Obesity is having an excessive amount of body fat in relation to lean body mass that may impair health.
The primary cause is an energy imbalance between calories consumed and expended.
Treatment goals include to lose 5-10% of body weight or 0.5-1 kg (1-2 lb)/week for 6 months and regain of <3 kg in 2 years and sustained reduction of waist circumference of at least 4 cm.
Strategies are aiming for realistic goals and a multidisciplinary approach that is a combination of dietary change, physical activity and behavioral modification.
Patients with type 2 diabetes mellitus (T2DM) who are overweight or obese but have high cardiorespiratory fitness (CRF)* may have a reduced risk of heart failure (HF), according to a study presented at EPI Lifestyle 2020.
Real-world data from the PCORnet* Bariatric Study suggest that Roux-en-Y gastric bypass (RYGB) may be preferable to sleeve gastrectomy (SG) in inducing and maintaining type 2 diabetes (T2DM) remission.
Use of combination therapy with sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for treating type 2 diabetes mellitus (T2DM) or obese patients yields favourable effects on glycaemic control, body weight and systolic blood pressure (SBP) without increasing the incidence of adverse events, according to the results of a meta-analysis.
In the primary care setting, adding liraglutide to intensive behavioural therapy (IBT) conferred greater weight loss than IBT alone among individuals with obesity, results from the phase IIIB SCALE* IBT study showed.
Both obesity and excessive weight gain in middle age bear a heightened risk of cognitive impairment at old age, according to a study. Conversely, excessive weight loss is not associated with a risk increase, although it may serve as an early marker of a “long and insidious process of cognitive decline.”
Bariatric surgery is beneficial to nondiabetic Asian patients with obesity, delivering sustained weight loss in addition to normalizing sugar levels and insulin resistance within 1–3 years of the procedure, as reported in a Singapore study.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.